Ganeden, Schiff Partner for Probiotic Study

CLEVELANDGaneden Biotech and Schiff Nutrition International Inc. will partner to fund a study led by the University of Reading, London. The study will determine the effects of GanedenBC30 on mature healthy adults with changing immunity and gastrointestinal (GI) needs.

The patented natural probiotic manufactured by Ganeden Biotech, GanedenBC30 (Bacillus coagulans GBI-30, 6086) has shown to support immune and digestive systems, according to the company. Schiff purchased the rights to GanedenBC30 in June 2011. The company  developed the Schiff Sustenex® and Digestive Advantage® lines of probiotic products.

The study will be a prospective, double blind, placebo-controlled, randomized, single centered crossover study in 40 healthy elderly (65 to 80 years old) individuals.

Glenn Gibson, professor of Food Microbial Sciences at the University of Reading and president and founding member of the International Scientific Association for Probiotics and Prebiotics is the senior author of the study, titled, "A randomized, double-blind, placebo controlled crossover study to determine the effect of probiotic GanedenBC30 on the immune function and gut microbiota of elderly persons."

Through the study, both Ganeden and Schiff look to gain a better understanding of the gut with age.

Ganeden previously worked with Unistraw International Ltd. to develop a GanedenBC30-rich straw.